Skip to Content

WisdomTree BioRevolution ETF WDNA

Medalist Rating as of | See WisdomTree Investment Hub

Morningstar’s Analysis WDNA

Will WDNA outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

WisdomTree BioRevolution ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings WDNA

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 22.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novonesis AS Class B

2.65 61,511
Basic Materials

Twist Bioscience Corp

2.55 59,314
Healthcare

Blueprint Medicines Corp

2.38 55,374
Healthcare

Iovance Biotherapeutics Inc

2.38 55,362
Healthcare

Natera Inc

2.13 49,526
Healthcare

Eli Lilly and Co

2.12 49,216
Healthcare

Vericel Corp

2.08 48,323
Healthcare

Geron Corp

2.07 48,174
Healthcare

Fate Therapeutics Inc

2.01 46,739
Healthcare

Agios Pharmaceuticals Inc

1.72 40,049
Healthcare